http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48#Head
http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48#assertion
http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48#provenance
http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48#pubinfo
http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48#assertion
http://purl.obolibrary.org/obo/DOID_1040
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_1040
http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB09054
http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48#association
http://www.w3.org/2000/01/rdf-schema#label
zydelig is a kinase inhibitor indicated for the treatment of patients with relapsed chronic lymphocytic leukemia cll in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co morbidities 1 1 relapsed follicular b cell non hodgkin lymphoma fl in patients who have received at least two prior systemic therapies 1 2 relapsed small lymphocytic lymphoma sll in patients who have received at least two prior systemic therapies 1 3 limitation of use zydelig is not indicated and is not recommended for first line treatment of any patient 1 1 1 2 1 3 zydelig is not indicated and is not recommended in combination with bendamustine and or rituximab for the treatment of fl 1 2 accelerated approval was granted for fl and sll based on overall response rate improvement in patient survival or disease related symptoms has not been established continued approval for these indications may be contingent upon verification of clinical benefit in confirmatory trials zydelig is indicated in combination with rituximab for the treatment of patients with relapsed chronic lymphocytic leukemia cll for whom rituximab alone would be considered appropriate therapy due to other co morbidities limitation of use zydelig is not indicated and is not recommended for first line treatment of patients with cll zydelig is indicated for the treatment of patients with relapsed follicular b cell non hodgkin lymphoma fl who have received at least two prior systemic therapies accelerated approval was granted for this indication based on overall response rate see clinical studies 14 2 limitation of use zydelig is not indicated and is not recommended for first line treatment of patients with fl zydelig is not indicated and is not recommended in combination with bendamustine and or rituximab for the treatment of fl zydelig is indicated for the treatment of patients with relapsed small lymphocytic lymphoma sll who have received at least two prior systemic therapies accelerated approval was granted for this indication based on overall response rate see clinical studies 14 3 limitation of use zydelig is not indicated and is not recommended for first line treatment of patients with sll
http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB09054
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48#provenance
http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48#pubinfo
http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48#sig
http://purl.org/nanopub/x/hasSignature
bXMzOf/OTp+iPy9keH4ViShmSIn1R3f/b5cn4jgYiHRlnWWQBqiOvOpF1ZjOTc2iwt3ohRUf891FknMRP4zEWo6StoWfSwxecoUp2mcjfAVEkB6VsW43jvX/lUXO1vS/WkLWFnrmjc53CK21X1muncMRunPZvvCNZLiDh97Scsw=
http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48
http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48
http://purl.org/dc/terms/created
2021-06-12T14:32:34.213+02:00
http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs